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Abstract
Background: To analyse the maternal mortality ratio, demographic and pregnancy related details in women who
suffered a fatal amniotic fluid embolism (AFE) in China.
Methods: A retrospective population based study using data collected as part of the National Maternal Mortality
Surveillance System between 1996 and 2013. Data were collected onto a standardised form from women whose
cause of death was listed as being secondary to AFE.
Results: Records were available for 640 deaths. Over the 17 year period the maternal mortality ratio for AFE
decreased from 4.4 per 100,000 births (95 % confidence interval (CI):2.72–6.12) to 1.9 per 100,000 births (95 % CI:1.
35–2.54). Over the same period the proportion of maternal deaths secondary to AFE increased from 6.8 to 12.5 %.
The mean age of women who died was 30.1 years and the onset of the AFE occurred prior to delivery in 39 %. The
most prominent presenting features included premonitory symptoms (29 %), acute fetal compromise (28 %),
maternal haemorrhage (16 %) and shortness of breath (15 %).
Conclusions: Maternal mortality secondary to AFE has decreased in China, however at a slower rate than mortality
secondary to other conditions. Active surveillance is recommended to assess case fatality rates, risk factors and
other lessons specific to this population.
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Background
In September 2000 the United Nations Millennium
Declaration committed world leaders to improving the
health and wellbeing of member states by the year 2015
through a number of specific Development Goals [1].
Millennium Development Goal 5 (MDG5) aims to im-
prove maternal health and more specifically, Target 5.A.
aims to reduce the maternal mortality ratio (MMR) by
three quarters for the time period 1990–2015 [2]. Cur-
rently, approximately 290,000 women die each year from
pregnancy related complications [3]. Throughout the
world there are significant differences in the MMR sec-
ondary to a number of factors including the underlying
socioeconomic state of the population, geographical lo-
cation, access to contraception and access to skilled
birth attendants [3–5].
China has had well documented success in reducing their
maternal mortality in line with MDG5 [6]. This has been in
large part secondary to the transition to women giving birth
in a hospital environment [7]. This has been supported by
widespread media campaigns, subsidies to promote hospital
based birth, infrastructure improvements as well as in-
creased training for staff involved in the care of pregnant
women [8, 9]. The majority of the decrease in maternal
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mortality can be explained by a reduction in more poten-
tially preventable causes of mortality such as haemorrhage,
hypertensive disorders of pregnancy and sepsis [10].
Amniotic fluid embolism (AFE) is a rare complication
of pregnancy with a comparatively high mortality [11]. It
often presents as the sudden onset of cardiovascular col-
lapse, respiratory compromise and disseminated intra-
vascular coagulation. AFE is a poorly understood
condition whose management requires prompt and
timely access to providers with training in maternal re-
suscitation as well as resources to manage the potential
cardiovascular, respiratory and haematological com-
promise [11]. In contrast to developing nations, in well-
resourced countries such as Australia, New Zealand and
the United Kingdom AFE is a leading cause of maternal
mortality [12–14]. However, there has been little atten-
tion focused on AFE as a contributor to maternal mor-
tality in developing nations.
As countries continue to work towards reducing
their maternal mortality, conditions such as AFE are
likely to become more prominent as other more pre-
ventable causes decline in frequency. The aim of this
present study was to analyse the MMR, demographic
and pregnancy related details in women who suffered
a fatal AFE in China between January 1 1996 and
September 30 2013.
Methods
This study was designed as a population based study
using data collected as part of the National Maternal
Mortality Surveillance System (NMMSS). The NMMSS
is part of the National Maternal and Child Health Sur-
veillance System (MCHSS) and was established by the
Chinese Ministry of Health in 1989. The process of the
establishment of the NMMSS and the methods of data
collection have been described in detail elsewhere [10].
From 1996 to 2006, the MCHSS covered 176 surveil-
lance districts/counties representing approximately 80
million people with an annual number of live births
ranged from 493,662 to 622,856. After 2006, the MCHSS
was expended to 336 surveillance districts/counties
covering approximately 140 million people with an
annual number of live births ranged from 1,759,539 to
2,111,365.
For the purposes of the NMMSS a maternal death is
classified in line with the World Health Organization
(WHO) definition [15] and is the death of a woman
while pregnant or within 42 days of termination of
pregnancy, irrespective of the duration and of the
pregnancy, from any cause related to or aggravated by
pregnancy or its management, but not from acciden-
tal or incidental causes.
A standardised procedure is used to determine the
cause of death for each case that each maternal death is
reviewed by four levels of committees (county/district
review committee, municipal review committee, provin-
cial review committee and the National Review Com-
mittee) [16]. If a maternal death occurs, the death is
investigated by trained obstetricians including inter-
views of the family, midwives, physicians and nursing
staffs. The information were collected using a standar-
dised form on prenatal care; history of the pregnancy;
course of delivery; the date of delivery and death; cause
of maternal death and details of the treatment provided.
This information is then reviewed by a county/district
review committee to determine the cause of death and
identify factors contributing to death. A maternal death
secondary to AFE is defined either as a clinical diagno-
sis (acute hypotension or cardiac arrest, acute hypoxia,
acute pulmonary embolism, cardiovascular collapse,
disseminated intravascular coagulation, renal failure
and a series of pathological changes in the absence of
any other potential explanation for the symptoms and
signs observed) or as a post mortem diagnosis (pres-
ence of fetal debris in the circulation). The municipal
and provincial maternal and child health institutions
review and verify the investigative reports. Finally, com-
mittees at the provincial and national level re-examine
the results submitted by the subordinate committee
and make the final decision as to the likely cause of
death. The ascertainment rate of maternal death was
approximately 96 % for all causes of death.
For the purposes of this study the NMMSS database
was examined for maternal deaths between January 1
1996 and September 30 2013 where AFE was re-
corded as the cause of death. Data was then extracted
from the mortality records using a standardised data
collection form based on those originally developed
by the Australasian Maternity Outcomes Surveillance
System (AMOSS) [17], and then modified by the
National Office for Maternal and Child Health Sur-
veillance. The modified survey form included baseline
demographic and pregnancy factors, obstetric inter-
ventions, the location of the woman’s initial presenta-
tion/collapse, the most prominent initial presenting
feature, other associated features, therapy required,
results of relevant investigations and maternal and
perinatal outcomes. Premonitory symptoms are de-
fined as those present before the abrupt change in
maternal condition that led to the diagnosis of AFE
and may include: breathlessness, chest pain, feeling
cold, light headedness, restlessness, distress, panic, a
feeling of pins and needles in the fingers, nausea and
vomiting. A stillbirth was defined in accordance with
WHO criteria, that being a baby born with no signs
of life after 28 weeks gestation. A neonatal death was
defined as death occurring within the first 28 days
post-delivery.
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Statistical methods
The MMR was calculated from the number of maternal
deaths per 100 000 live births. The 95 % confidence in-
tervals (CI) of the MMR in urban and rural areas were
calculated by assuming that the counts follow a Poisson
distribution. We did statistical analyses with SPSS soft-
ware (version 16.0; SPSS Inc., Chicago, IL, USA).
Results
Over the course of the study period there were 664 re-
corded deaths secondary to AFE, of which summary
medical records were available for 640 cases. Over the
corresponding period there were 20,006,880 live births,
giving an estimated maternal mortality from AFE of
1:30,131 births (95 % CI: 1:26001–1: 32611 births). The
MMR for AFE over the study period decreased from 4.4
per 100,000 (95 % CI 2.72–6.12) in 1996 to 1.9 per
100,000 (95 % CI 1.35–2.54) in 2013 (Fig. 1a). Over the
corresponding period the proportion of maternal deaths
secondary to AFE increased from 6.8 % in 1996 to
12.5 % in 2013 (Fig. 2).
The demographic details of the women who died are
shown in Table 1. The mean age of the women who died
was 30.1 (±5.4) years. Eighty four percent of pregnancies
were singleton. The onset of the AFE episode occurred
prior to delivery in 39 % and after delivery in 53 % (un-
known in 8 %) (Table 2). For those cases that occurred
postpartum, 78 % occurred in the first 60 min after de-
livery (56 % in the first 30 mins, 22 % between 30–60
min after delivery). The location of the AFE episode was
Fig. 1 a Maternal mortality secondary to amniotic fluid embolism in China, 1996–2013. b Maternal mortality secondary to amniotic fluid
embolism in urban and rural China, 1996–2013
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recorded as being at home in 8.4 % of cases, in the deliv-
ery suite in 36 % of cases, the operating theatre in 13 %
and the maternity ward in 14 %. Twenty four percent of
women did not give birth whilst 60 % had a vaginal birth
and 16 % a caesarean delivery.
The most prominent initial presenting feature and the
associated presenting features varied by the pregnancy
state at the onset of the collapse (Figs. 3 and 4). Overall,
premonitory symptoms were the most commonly de-
scribed initial presenting feature (29 %) followed by
acute fetal compromise (28 %), maternal haemorrhage
(16 %) and shortness of breath (15 %).
Details of the treatment required are shown in Table 3.
Cardiopulmonary resuscitation was performed in 75 %
of women whilst 40 % required intubation and ventila-
tion. Thirty seven percent of women were administered
blood or blood products and a hysterectomy was per-
formed in 18 %. The time from the onset of the AFE epi-
sode until death was confirmed is shown in Fig. 5. An
autopsy was performed in 43 women (6.7 %) and in 10
(23.3 %) there was documented evidence of material
consistent with amniotic fluid in the maternal pulmon-
ary circulation.
Only limited neonatal data were able to be ex-
tracted from the NMMSS. Twenty four percent of
women did not give birth (died undelivered), for the
remaining 76 % of women (n = 486) information was
only available for 160 of which there were 91 still-
births, 30 neonatal deaths and 39 neonates surviving
past 27 days of age.
Discussion
Between 1996 and 2013 there were 664 deaths classi-
fied as being secondary to AFE in the regions of
China that participated in the NMMSS maternal mor-
tality surveillance. Over this time period the MMR
secondary to AFE declined from 4.4 to 1.9 per
100,000 births however the proportion of maternal
Table 1 Demographic and obstetric characteristics of the maternal
deaths secondary to amniotic fluid embolism in China, 1996–2013
Demographic and obstetric characteristics Number Percent
Age (year) Mean (SD) 30.1 (5.4)
Age (year)
< 25 85 13.3
25–29 158 24.7
30–34 227 35.5

















Three or more 12 1.9
Unknown 75 11.7




> =5 305 47.7
Unknown 28 4.4
Fig. 2 The proportion of of maternal deaths secondary to amniotic fluid embolism in China, 1996–2013
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deaths secondary to AFE increased from 6.8 % in
1996 to 12.5 % in 2013. Although the proportion of
maternal deaths secondary to AFE has increased over
this period, the absolute numbers have decreased
most likely reflecting the more rapid decline in deaths
secondary to more preventable and common causes
such as haemorrhage.
The major strength of this study is the large num-
ber of maternal deaths secondary to AFE. The 664
deaths reported here represent internationally the lar-
gest cohort of maternal deaths to have been reported.
As the data was collected over a 17 year time period
and across a broad geographical area, it provides con-
temporary information on the trends in MMR from
AFE over this time period and also the differences
across urban versus rural China. However, as data for
these cases was collected retrospectively from a stan-
dardised dataset, only limited data that was routinely
entered as part of the NMMSS data collection process
was available for review. Population based data collec-
tion without the use of additional criteria to exclude
false positive cases may lead to an overestimation of
the true incidence [18]. As there is currently no ac-
tive surveillance of AFE in China it is not possible to
report a case fatality rate, overall incidence of AFE as
well as risk factors for AFE and factors associated
with survival from AFE. Data in relation to fetal out-
comes was limited by a lack of routine neonatal data
collection in the NMMSS. As AFE is a diagnosis of
exclusion [19], maternal autopsy is important to help
exclude other potential causes of collapse and it has
been a consistent message from the UK Confidential
Enquiries that access to high quality pathology ser-
vices is required for maternal deaths [14, 20] and
guidelines for the performance of a maternal autopsy
are available [21]. Of the 664 deaths reported here,
only 43 (6.5 %) women underwent a post mortem
examination, potentially secondary to a historical lack
of access to pathology services. This low rate of post
mortem examination may lead to higher numbers of
both false positive and false negative diagnoses and
suggest that efforts to further improve the maternal
mortality in China should also be done in conjunction
Table 2 Delivery and collapse details of the maternal deaths
secondary to amniotic fluid embolism in China, 1996–2013
Delivery and collapse details Number Percent













Non-instrumental vaginal 290 45.3
Instrumental vaginal 93 14.5
Caesarean 103 16.1
Location of onset of symptoms
Home 54 8.4
Maternity ward 91 14.2
Labour room 6 0.9
Theatre 85 13.3
Delivery Suite 227 35.5
Other 28 4.4
Unknown 149 23.3
Pregnancy state at onset of collapse
Pre-labour 30 4.7
First stage 112 17.5
Second stage 111 17.3
Post delivery 337 52.7
Unknown 50 7.8
Time from delivery until onset of symptomsb
0 ~ 0.5 h after delivery 141 55.73
0.5 ~ 1 h after delivery 55 21.74
1 ~ 1.5 h after delivery 23 9.09
1.5 ~ 2 h after delivery 8 3.16







Table 2 Delivery and collapse details of the maternal deaths
secondary to amniotic fluid embolism in China, 1996–2013
(Continued)
Home 39 6.1
On the way to hospital 42 6.6
Other 5 0.8
aIncluding termination of pregnancy
bIf delivered prior to onset of symptoms
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with efforts to increase the access to and uptake of
maternal autopsy.
The decrease in the MMR from AFE in this popula-
tion is likely to be secondary to the considerable efforts
focused on improving maternal mortality in China since
the establishment of the Millennium Development
Goals. In line with MDG5, the Chinese government
invested considerable resources in decreasing maternal
mortality. Projects such as the “Reducing Maternal Mor-
tality and Eliminating Newborn Tetanus” have aimed to
promote hospital based births for rural women as well as
improve resources and training of staff [22]. However,
despite the decrease, the MMR reported here is similar to
other developing countries (ranged between 1.8–5.9 per
100,000 deliveries) [23] and higher than in many
developed countries. The most recent triennial confiden-
tial enquiry into maternal deaths in the UK and Ireland re-
ports an MMR from AFE of 0.33 per 100,000 [14] whilst
data from Australia reports an MMR of 0.6 per 100,000
[12]. A number of factors may explain these differences,
including socio-economic factors as well as timely access
to skilled health care providers in the event of maternal
compromise. Previously, the MMR in rural versus urban
areas in China has shown significant disparity [10] with a
larger number of more preventable deaths [16]. This gap
between rural and urban areas now appears to be narrow-
ing [24] and in the data presented here, the MMR for AFE
is now similar for both rural and urban areas.
In this study, the most prominent initial presenting
feature differed depending on the pregnancy state of the
Fig. 3 The single most prominent initial presenting feature by pregnancy state at onset of collapse of maternal deaths secondary to amniotic
fluid embolism in China, 1996–2013
Fig. 4 Overall presenting features by pregnancy state at onset of collapse of maternal deaths to amniotic fluid embolism in China, 1996–2013
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mother. Previous studies have generally not differenti-
ated the presenting features in relation to the preg-
nancy state and in this regard the data presented here
provides useful information that may assist with more
timely recognition of an AFE episode. Women whose
onset of the AFE occurred in utero showed a high
incidence of acute fetal compromise as the initial
presenting feature, most likely because the utero-
placental unit is often very sensitive to changes in the
maternal haemodynamic state. The development of
acute fetal compromise, especially in the presence of
abnormal maternal signs and symptoms, should alert
the care provider of the potential for impending ma-
ternal deterioration and potentially prompt the mobil-
isation of additional resources.
Currently in China there is no widespread system in
place to monitor rare conditions of pregnancy. Obstetric
surveillance systems such the AMOSS and the UK Ob-
stetric Surveillance System (UKOSS) have demonstrated
the benefit that these systems can have in furthering the
understanding of rare conditions of pregnancy [25] as
well as in rapidly responding to emerging issues that can
impact on pregnant women [26]. In relation to AFE, the
lack of an active surveillance system means potentially
important clinical and health systems information spe-
cific to the Chinese population and maternity care con-
text regarding risk factors for AFE, comparisons of
women who survive and don’t survive their AFE as well
as overall case fatality rates are not able to be reported.
Given the comparatively high MMR for AFE reported
here, the establishment of a surveillance system for AFE
and other rare conditions of pregnancy is likely to be a
worthwhile investment, not only in China, but also in
other developing nations who have undergone signifi-
cant reductions in maternal mortality.
Conclusions
The MMR secondary to AFE in a large Chinese popula-
tion declined by over 50 % in the 17 year period from
1996–2013. Over this same time period and as a likely
consequence of a reduction in deaths from more pre-
ventable causes, the proportion of maternal deaths sec-
ondary to AFE increased. The likely reasons for the
decline in the mortality ratio from AFE include the
greater urbanisation of the Chinese population in con-
junction with improved health care in more disadvan-
taged regions. As other developing nations are likely to
go through similar changes in the risk profile of mater-
nal deaths, there are a number of potential lessons to be
learned. To more comprehensively study rare disorders
of pregnancy, the use of surveillance systems similar to
that used in Australia/New Zealand (AMOSS) and the
UK (UKOSS) potentially provide more useful informa-
tion then that derived from conventional mortality
reporting. As AFE may present suddenly and require
prompt and significant multi-disciplinary resources to
effectively manage, the provision of appropriate training
and infrastructure in delivery settings is important to
improve outcomes and may require significant invest-
ment in more isolated regions.
Fig. 5 Time from the onset of the amniotic fluid embolism episode until death, maternal deaths secondary to amniotic fluid embolism in
China, 1996–2013
Table 3 Treatment required during the management of the
maternal deaths secondary to Amniotic fluid embolism in China,
1996–2013
Treatment Number Percent
Cardiopulmonary resuscitation 478 74.7
Intubation/Ventilation 258 40.3
Hysterectomy 113 17.7
Recombinant Factor VIIa 32 5.0
Blood and blood products 239 37.3
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